SCHEMBL1740852

SCHEMBL1740852

Cc1cccc(NC(=N)N)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.67
HSD17B10 Q99714 1/20 0.58
SIGMAR1 Q99720 2/20 0.57
GRIN2D O15399 1/20 0.57
GRIN3B O60391 1/20 0.57
GRIN1 Q05586 1/20 0.57
GRIN2A Q12879 1/20 0.57
GRIN2B Q13224 1/20 0.57
GRIN2C Q14957 1/20 0.57
GRIN3A Q8TCU5 1/20 0.57
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
MAPT P10636 3/20 0.53
ALDH1A1 P00352 1/20 0.53
GAA P10253 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
CYP2D6 P10635 3/20 0.51
POLB P06746 1/20 0.51
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19136056 0.90 CYP1A2 (0.56) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
Nitric Acid SCHEMBL1880262 0.88 CYP1A2 (0.54) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL1741887 0.85 CYP1A2 (0.59) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
Hydrochloric Acid SCHEMBL28340523 0.84 CYP1A2 (0.57) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL6422898 0.83 HSD17B10 (0.62) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL2327286 0.81 HSD17B10 (0.56) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL20037286 0.80 CYP1A2 (0.57) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL22995856 0.80 CYP1A2 (0.67) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL166848 0.80 HSD17B10 (0.69) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL20714982 0.80 CYP1A2 (0.43) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4180482-B1 MOISTURE-CURABLE COMPOSITION NITTO KASEI CO LTD (JP) 2025-12-03 EP disclosed
US-12479869-B2 Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product NITTO KASEI CO., LTD. (JP) 2025-11-25 US disclosed
EP-4174053-B1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT NITTO KASEI CO LTD (JP) 2025-11-19 EP disclosed
EP-4569023-A1 COMBINATION OF CATALYTIC COMPONENTS PolyU GmbH (DE) 2025-06-18 EP disclosed
CN-115516041-B Curing catalyst for curing polymer, method for producing same, moisture-curable composition, and method for producing cured product 日东化成株式会社 2024-06-28 CN disclosed
WO-2024033348-A1 COMBINATION OF CATALYTIC COMPONENTS POLYU GMBH (DE) 2024-02-15 WO disclosed
US-20230234976-A1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT NITTO KASEI CO., LTD. (JP) 2023-07-27 US disclosed
EP-4180482-A1 MOISTURE-CURABLE COMPOSITION Nitto Kasei Co., Ltd. (JP) 2023-05-17 EP disclosed
EP-4174053-A1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT Nitto Kasei Co., Ltd. (JP) 2023-05-03 EP disclosed
EP-2837660-B1 CURABLE COMPOSITION, AND CURED SYNTHETIC RESIN USING SAME UNIV MIE (JP) 2021-07-14 EP disclosed
WO-2006047415-A2 FACTOR XA COMPOUNDS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed
US-20050136017-A1 Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin L'OREAL S.A. (FR) 2005-06-23 US disclosed
US-20050129645-A1 Hair shaping composition comprising at least one non-hydroxide imine L'OREAL 2005-06-16 US disclosed
EP-1532963-A1 Composition for straightening the hair comprising at least one imine not being an hydroxide L'OREAL (FR) 2005-05-25 EP disclosed
EP-1532960-A1 Hair styling composition containing a non-hydroxide imine L'OREAL (FR) 2005-05-25 EP disclosed
EP-0918460-A1 METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS CAMBRIDGE NEUROSCIENCE, INC. (US) 1999-06-02 EP disclosed
WO-1998004131-A1 METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS CAMBRIDGE NEUROSCIENCE, INC. (US) 1998-02-05 WO disclosed
EP-0726706-A4 N,N'-DISUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS OREGON STATE (US) 1997-11-19 EP disclosed
EP-0726706-A1 N,N'-DISUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS STATE OF OREGON BY AND THROUGH OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OREGON HEALTH SC. UNIV. AND OREGON STATE UNIV. (US) 1996-08-21 EP disclosed
WO-1993017555-A1 N,N'-DISUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) 1993-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479869-B2 Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product KDM2B, SETDB1, ASH2L CYP1A2 512/4885HSD17B10 2247/4885SIGMAR1 3942/4885
US-20230234976-A1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT KDM2B, SETDB1, ASH2L CYP1A2 512/4885HSD17B10 2247/4885SIGMAR1 3942/4885
US-20050129645-A1 Hair shaping composition comprising at least one non-hydroxide imine KRT18, INHA, H1-5 CYP1A2 2186/4885HSD17B10 1576/4885SIGMAR1 2720/4885
US-20050136017-A1 Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin BHMT, KRT18, INMT CYP1A2 2496/4885HSD17B10 2663/4885SIGMAR1 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.